Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup - Ludwig, Heinz; Dimopoulos, Meletios A; Moreau, Philippe; Chng, Wee-Joo; Goldschmidt, Hartmut; Hájek, Roman; Facon, Thierry; Pour, Ludek; Niesvizky, Ruben; Oriol, Albert; Rosiñol, Laura; Suvorov, Aleksandr; et al. (Leukemia & lymphoma, 2017)
Keywords: Oligopeptides; Female; ženské pohlaví; Neoplasm Recurrence, Local; Bortezomib; lidé; oligopeptidy; mnohočetný myelom; následné studie; míra přežití; Antineoplastic Combined Chemotherapy Protocols; prognóza; protokoly protinádorové kombinované chemoterapie; Follow-Up Studies; Male; Aged; dexamethason; Dexamethasone; lokální recidiva nádoru; Prognosis; Survival Rate; bortezomib; Multiple Myeloma; senioři; mužské pohlaví; Humans